MV BioTherapeutics SA

MV Biotherapeutics (MV Bio) is a early stage Swiss biotherapeutics company, and a spin-off from the Institute for Research in Biomedicine (IRB) in Bellinzona, Switzerland. MV Bio is developing first-in-class mucosal immune enhancers for the treatment of IBD/Ulcerative Colits and other indications. MV Bio has discovered the reciprocal shaping of the intestinal immune system and microbiota by adenosine triphosphate (ATP) released by bacteria and has generated a patented technology platform based on the delivery of an ATP-degrading enzyme, apyrase, to the intestine via different vectors.